Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: Results of a 4-week, randomized, double-masked, parallel-group study

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2219-2227

  Bartlett, Jimmy D ^a   Holland, Edward J ^b   Usner, Dale W ^c   Paterno, Michael R ^c   Comstock, Timothy L ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b CINCINNATI EYE INSTITUTE   (United States)

^c BAUSCH AND LOMB   (United States)

Author keywords

Dexamethasone; Ester steroid; Ketone steroid; Loteprednol etabonate; Ocular inflammation; Tobramycin

Indexed keywords

ARTIFICIAL TEAR; DEXAMETHASONE PLUS TOBRAMYCIN; LOTEPREDNOL ETABONATE PLUS TOBRAMYCIN;

ADULT; AGED; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; ELECTRONIC MEDICAL RECORD; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR FOREIGN BODY; MALE; MULTICENTER STUDY; NORMAL HUMAN; OCULAR PRURITUS; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PHOTOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANDROSTADIENES; DEXAMETHASONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TOBRAMYCIN;

EID: 50149102171     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802231981     Document Type: Review

References (16)

1. Notivol R, Bertin D, Amin D, et al. Comparison of topical tobramycin-dexamethasone with dexamethasone-neomycin-polymyxin and neomycin-polymyxin-gramicidin for control of inflammation after cataract surgery: results of a multicenter, prospective, three-arm, randomized, double-masked, controlled, parallel-group study. Clin Ther 2004;26:1274-85
2. Bodor N, Retrometabolic approaches to drug targeting. In: Rapaka RS, ed. Membranes and Barriers: Targeted Drug Delivery. NIDA Research Monograph 154. Rockville, MD: National Institutes of Health, 1995:1-85
3. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000;20:58-101
4. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J 2005;7:E820-33
5. Whitcup SM, Ferris 3rd, FL. New corticosteroids for the treatment of ocular inflammation. Am J Ophthalmol 1999;127:597-9
6. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33-55
7. Weijtens O, Schoemaker RC, Romijn FP, et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002;109:1887-91
8. Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J Ocul Pharmacol Ther 1998;14:153-8
9. TobraDex Prescribing Information, 2005, Alcon Pharmaceuticals/ Laboratories, Inc.: Fort Worth, Texas, USA
10. Zylet Prescribing Information, 2005, Bausch & Lomb, Inc.: Tampa, Florida, USA
11. Holland EJ, Bartlett JD, Paterno MR, et al. The effects of loteprednol/ tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008;27:50-5
12. Wang WW, Mehrotra DV, Chan IS, et al. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat 2006;16:429-41
13. Pavesio CE, DeCory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 2008;92:455-9
14. Guillon M, Maissa C, Pouliquen P, et al. Effect of povidone 2% preservative-free eyedrops on contact lens wearers with computer visual syndrome: pilot study. Eye Contact Lens 2004;30:34-9
15. Bartlett JD, ed. Ophthalmic Drug Facts, 19th edn. St. Louis: Wolters Kluwer Health, 2008
16. White EM, Macy JI, Bateman KM, et al. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/ tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin 2008; 24:287-96